BioSpace News Archive

Ionis Pharmaceuticals, Inc. and Akcea Therapeutics, Inc. announced Phase 3 data showing that inotersen-treated patients with hereditary ATTR (hATTR) amyloidosis who were treated for up to 27 months in the NEURO-TTR and open-label extension (OLE) studies continued to demonstrate sustained benefit in measures of quality of life and neuropathy.

GT Biopharma Inc. (OTCQB “GTBP” and Euronext Paris “GTBP.PA”) today announced that it has completed the analysis of pharmacokinetic data from its Phase 1 clinical trial for GTP-004, its promising treatment for the symptoms of myasthenia gravis.

Astellas Pharma Inc. and Seattle Genetics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC), for patients with locally advanced or metastatic urothelial cancer who were previously treated with checkpoint inhibitors (CPI).

BioLife Solutions Inc. and SAVSU Technologies announced that the USPTO has issued a notice of allowance for a second patent application titled “Biologic Stability, Delivery Logistics and Administration of Time and/or Temperature Sensitive Biologic Based Materials”.

MedPharm Ltd., a leading provider of contract topical and transdermal product design and formulation development services, is pleased to announce an investment by Ampersand Capital Partners.

Arpeggio Biosciences will use its proprietary technology to identify immediate biological and genetic changes promoted by specific drug-target interactions

Emmaus Life Sciences (Emmaus) announced today it has opened an office in Midtown Manhattan to support the commercial launch of EndariTM (L-glutamine oral powder).

Bayer announced that its collaboration partner Loxo Oncology, Inc., has completed the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for larotrectinib for the treatment of adult and pediatric patients.

Allecra Therapeutics announced positive top-line results from the Phase 2 study of its lead antibiotic candidate, an extended spectrum β-lactamase inhibitor known as AAI101.

Protagonist Therapeutics, Inc. announced that the Company is discontinuing the Phase 2b PROPEL study of PTG-100, its investigational oral GI-restricted alpha-4-beta-7 integrin antagonist peptide, in patients with moderate to severe ulcerative colitis (UC).